129 related articles for article (PubMed ID: 7925829)
1. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
Wüllner U; Pakzaban P; Brownell AL; Hantraye P; Burns L; Shoup T; Elmaleh D; Petto AJ; Spealman RD; Brownell GL
Exp Neurol; 1994 Apr; 126(2):305-9. PubMed ID: 7925829
[TBL] [Abstract][Full Text] [Related]
2. Cocaine congeners as PET imaging probes for dopamine terminals.
Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
[TBL] [Abstract][Full Text] [Related]
3. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism.
Hantraye P; Brownell AL; Elmaleh D; Spealman RD; Wüllner U; Brownell GL; Madras BK; Isacson O
Neuroreport; 1992 Mar; 3(3):265-8. PubMed ID: 1515582
[TBL] [Abstract][Full Text] [Related]
4. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
5. SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
Fischman AJ; Babich JW; Elmaleh DR; Barrow SA; Meltzer P; Hanson RN; Madras BK
J Nucl Med; 1997 Jan; 38(1):144-50. PubMed ID: 8998169
[TBL] [Abstract][Full Text] [Related]
6. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Exp Neurol; 2000 Oct; 165(2):342-6. PubMed ID: 10993693
[TBL] [Abstract][Full Text] [Related]
7. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography.
Rinne JO; Sahlberg N; Ruottinen H; Någren K; Lehikoinen P
Neurology; 1998 Jan; 50(1):152-6. PubMed ID: 9443472
[TBL] [Abstract][Full Text] [Related]
8. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
Imai H; Nakamura T; Endo K; Narabayashi H
Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746
[TBL] [Abstract][Full Text] [Related]
9. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
10. Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT.
Morris ED; Babich JW; Alpert NM; Bonab AA; Livni E; Weise S; Hsu H; Christian BT; Madras BK; Fischman AJ
Synapse; 1996 Nov; 24(3):262-72. PubMed ID: 8923667
[TBL] [Abstract][Full Text] [Related]
11. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
12. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
14. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
15. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
[TBL] [Abstract][Full Text] [Related]
16. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.
Brownell AL; Canales K; Chen YI; Jenkins BG; Owen C; Livni E; Yu M; Cicchetti F; Sanchez-Pernaute R; Isacson O
Neuroimage; 2003 Oct; 20(2):1064-75. PubMed ID: 14568476
[TBL] [Abstract][Full Text] [Related]
17. Unchanged striatal dopamine transporter availability in narcolepsy: a PET study with [11C]-CFT.
Rinne JO; Hublin C; Någren K; Helenius H; Partinen M
Acta Neurol Scand; 2004 Jan; 109(1):52-5. PubMed ID: 14653850
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
[TBL] [Abstract][Full Text] [Related]
19. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
20. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
